<DOC>
	<DOCNO>NCT02685046</DOCNO>
	<brief_summary>In proof-of-concept trial investigator study effect imatinib treatment biology mesenchymal-type colon cancer .</brief_summary>
	<brief_title>Imatinib Pre-operative Anti-Colon Cancer Targeted Therapy</brief_title>
	<detailed_description>Tumor biopsy patient newly diagnose colon cancer pre-screened RT-qPCR test identify tumor mesenchymal subtype . Patients mesenchymal-type tumor meet in- exclusion criterion treat imatinib `` window period '' normally precede surgery . Immediately follow tumor resection , biopsy take surgical specimen . Gene protein expression pre- post-treatments biopsy compare assess effect imatinib therapy PDGFR- cKIT-signalling mesenchymal gene expression profile .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female age ≥18 year 2 . Histologically proven adenocarcinoma colon ; 3 . Completed cancer stag CTabdomen CTthorax/Xthorax accord hospital 's standard care ; 4 . Confirmed eligibility surgery curative intent deem hospital 's multidisciplinary board ( MDB ) review ; 5 . An intratumoural gene expression profile PDGFRα , PDGFRβ , PDGFC KIT , indicative mesenchymal phenotype , accord diagnostic RTqPCR test ( i.e . 50 % chance mesenchymal phenotype ) ; 6 . Minimum four properly store pretreatment biopsy gene expression analysis/ELISA ; 7. WHO performance status 0 1 ; 8 . Adequate haematology status organ function , define : Normal creatinine clearance ( ≥60 ml/min ( MRDR ) ) ALAT within 2.5x upper limit normal ( ULN ) PTINR &lt; 1.5 Leukocytes &gt; 1,5*10^9/L ; Hb &gt; 6.0 mmol/L ; platelet &gt; 100*10^9/L 9 . Willingness ability comply schedule visit , treatment plan laboratory test ; 10 . Written informed consent . 1 . The presence synchronous distant metastasis ; 2 . Current hospital standard care dictate subject undergo neoadjuvant therapy ; 3 . Concurrent participation another clinical trial use medicinal product , participation trial period three month prior current trial ; 4 . Women pregnant , plan become pregnant lactating study 30 day last dose imatinib ; 5 . Known HIV Hepatitis B/C infection ; 6 . Known symptomatic congestive heart failure ; 7 . Comorbidity require concomitant treatment drug act strong inducer CYP3A4 drug narrow therapeutic range influence imatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>